SCHEMBL2704449

SCHEMBL2704449

COc1ccc2c(c1)N(S(=O)(=O)c1ccc(C)cc1)Cc1cn(-c3ccccc3)nc1-2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.48
▸ LMNA P02545 3/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ CA12 O43570 2/20 0.48
▸ CA1 P00915 2/20 0.48
▸ CA2 P00918 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ HPGD P15428 1/20 0.48
▸ RYR2 Q92736 1/20 0.42
▸ MAPT P10636 4/20 0.41
▸ AURKA O14965 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ CCNE1 P24864 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ KCNN4 O15554 1/20 0.40
▸ KCNA3 P22001 1/20 0.40
▸ CTSG P08311 1/20 0.39
▸ CMA1 P23946 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2705497 0.93 CA12 (0.46) ALDH1A1LMNAKDM4ECA12CA1
SCHEMBL2704466 0.86 KCNN4 (0.54) ALDH1A1LMNACA12CA1CA2
SCHEMBL2705166 0.78 KDM4E (0.52) ALDH1A1LMNAKDM4EHPGDRYR2
SCHEMBL2703634 0.70 KMT2A (0.47) ALDH1A1LMNAKDM4EHPGDRYR2
SCHEMBL6800381 0.69 KDM4E (0.54) ALDH1A1LMNAKDM4EHPGDRYR2
SCHEMBL29101139 0.69 HSD11B1 (0.46) ALDH1A1LMNAKDM4EHPGDRYR2
SCHEMBL30274328 0.69 KDM4E (0.58) ALDH1A1LMNAKDM4EHPGDRYR2
SCHEMBL4928110 0.68 NPC1 (0.45) ALDH1A1LMNAKDM4ECA12CA9
SCHEMBL22451554 0.67 KMT2A (0.57) ALDH1A1LMNAKDM4EHPGDRYR2
SCHEMBL8465682 0.67 MAOB (0.51) ALDH1A1LMNAKDM4EHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2450358-A1 Fused, tricyclic sulfonamide inhibitors of gamma secretase Elan Pharmaceuticals Inc. (US) 2012-05-09 — — EP claimed
EP-2038280-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals Inc. (US) 2009-03-25 — — EP claimed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US claimed
WO-2007143523-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-12-13 — — WO claimed
EP-2450358-A1 Fused, tricyclic sulfonamide inhibitors of gamma secretase Elan Pharmaceuticals Inc. (US) 2012-05-09 — — EP disclosed
EP-2038280-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE Elan Pharmaceuticals Inc. (US) 2009-03-25 — — EP disclosed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US disclosed
WO-2007143523-A2 FUSED, TRICYCLIC SULFONAMIDE INHIBITORS OF GAMMA SECRETASE ELAN PHARMACEUTICALS, INC. (US) 2007-12-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 ALDH1A1 1779/4885LMNA 1368/4885KDM4E 3281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback